HILDEN, Germany, and CHENGDU, China, May 2, 2017 /PRNewswire/ --
Partnership with a leading Chinese IVD company with goal to accelerate penetration of the world's first complete Sample to Insight NGS solution in rapidly growing Chinese market
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a joint venture with Maccura Biotechnology Co., Ltd., a leading in vitro diagnostics (IVD) company in China. The joint venture, named MAQGEN plans to accelerate local adaptations, development and commercialization of the GeneReader NGS System in the rapidly growing clinical and clinical research markets in China. QIAGEN's GeneReader NGS System is the world's first complete Sample to Insight solution and makes the benefits of next-generation sequencing (NGS) accessible to any laboratory.
"We are very pleased to have formed this partnership with Maccura. The creation of MAQGEN lays the foundation to significantly accelerate and expand the availability of the GeneReader system in laboratories across China, thereby offering a state-of-the-art, seamlessly integrated NGS workflow with menu and other adaptations for the local market. China is the fastest-growing NGS market, and Maccura is China's fastest-growing major IVD company. Our strategy to work 'In China, With China' will boost both companies' presence in the IVD market in China," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area.
Click here for the full press release.
SOURCE QIAGEN N.V.